This content aligns with Goal 3: Good Health by critically evaluating the efficacy of prodrugs in treating attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED), highlighting the importance of optimizing pharmacokinetic and pharmacodynamic properties to ensure effective and safe management of these conditions. By focusing on the therapeutic benefits and potential side effects of medications like lisdexamfetamine and serdexmethylphenidate, the review underscores the need for tailored treatment strategies that can improve health outcomes for individuals affected by these disorders. Additionally, it supports Goal 10: Reduced Inequalities by addressing the importance of accessible and effective medication options for ADHD and BED, ensuring that all patients, regardless of their background, have the opportunity to receive appropriate care and resources to manage their conditions effectively while minimizing the risk of misuse and abuse.